Penisimplicissin is a funicone-like compound and antiviral agent. Penisimplicissin reduces the expression of AhR and viral nucleocapsid protein. Penisimplicissin improves the cell viability and morphological characteristics of CCoV-infected cells. Penisimplicissin inhibits CCoV infection. Penisimplicissin can be used in studies related to canine coronavirus infection.

PDL1 degrader-3 (comppund e24) is a CSN5-binding antitumor immunomodulator with a human CSN5 Kd of 4.53 μM. PDL1 degrader-3 inhibits CSN5 enzymatic activity, increases PD-L1 ubiquitination, and induces PD-L1 degradation via the ubiquitin-proteasome pathway, reducing PD-L1 expression on tumor cell membranes. PDL1 degrader-3 blocks PD-1/PD-L1 interaction, activates the tumor immune microenvironment, enhances tumor-infiltrating T-cell immunity, and inhibits activation of immunosuppressive MDSCs and Tregs. PDL1 degrader-3 exerts antitumor effects in mouse tumor models. PDL1 degrader-3 can be used for the research of colorectal cancer, lung cancer.

PDI-IN-5 (compound 30z) is an allosteric-covalent inhibitor targeting protein disulfide isomerase (PDI) with a 2-chloro-pyrrolopyrimidin-4-one scaffold, with an IC50 of 0.4 μM. PDI-IN-5 exhibits selectivity for ERp57 and GPX4, and inhibits glioblastoma. PDI-IN-5 can be used in glioblastoma-related research.

PDE4-IN-33 is a phosphodiesterase 4 (PDE4) inhibitor. PDE4-IN-33 reduces uric acid levels. PDE4-IN-33 PDE4-IN-33 can be used for the research of hyperuricemia and gout.

PDE3/4-IN-4 is an orally active PDE3A and PDE4B inhibitor with IC50 values of 10 nM and 9.4 nM, respectively. PDE3/4-IN-4 shows selective activity relative to most other PDE family members. PDE3/4-IN-4 modulates the cAMP/PKA/CREB signaling pathway. PDE3/4-IN-4 inhibits pro-inflammatory factor IL-6. PDE3/4-IN-4 reduces expression of inflammatory markers in liver tissue. PDE3/4-IN-4 attenuates liver fibrosis. PDE3/4-IN-4 limits liver damage in cholestatic and sepsis-induced liver disease mice models. PDE3/4-IN-4 can be used for the research of liver injury, cholestatic liver diseases, sepsis-induced liver injury.

PDE1-IN-12 (P78, the first compound in 12) is a PDE1 inhibitor. PDE1-IN-12 inhibits PDEl-mediated suppression of the dopamine D1 receptor intracellular pathway and can be used for narcolepsy.

PDE1-IN-11 (Compound 5cc) is an orally active and highly selective PDE1A1 inhibitor. PDE1-IN-11 increases intracellular cAMP and cGMP levels, activating the PKA-CREB and NO-cGMP-PKG signaling pathways, promoting osteoblast differentiation and bone formation, while suppressing osteoclastogenesis and bone resorption. PDE1-IN-11 is promising for research of postmenopausal osteoporosis (PMO) and other bone metabolism disorders.

PAT-347 sodium is an Autotaxin (ATX) inhibitor. ATX is a secretory enzyme that hydrolyzes lysophosphatidylcholine (LPC) and regulates lysophosphatidic acid (LPA) production in the blood.

PAT-078 is a type II autotaxin (ATX) inhibitor. PAT-078 mainly occupies the hydrophobic pocket of ATX, blocks the bottleneck region between the hydrophobic channel and the catalytic site, and does not interact with the zinc ion at the catalytic site.

PARP1-IN-56 (Compound RCY) is an I-labeled poly(ADP−ribose) polymerase (PARP1) inhibitor. PARP1-IN-56 can be radiolabeled with 211At or 125I for use as an α-emitting radiotherapeutic agent. PARP1-IN-56 can be used for the research of cancer.

PARP1-IN-53 (Compound 328) is a quinazolinone derivative and PARP1 inhibitor with a PARP1 IC50 of 0.1 nM and selectivity over PARP2, which has a PARP2 IC50 of 23 nM.PARP1-IN-53 can be used for the research of cancer.

PARP10-IN-1 is a PARP10 inhibitor with an IC50 of 1.8 μM, 2.7 μM, and >10-fold selectivity over most PARP family members, excluding PARP7 and PARP16.PARP10-IN-1 inhibits PARP10-mediated mono-ADP-ribosylation, including auto-MARylation of PARP10 and MARylation of its protein targets.PARP10-IN-1 is membrane permeable and inhibits PARP10-dependent MARylation in human embryonic kidney cells.PARP10-IN-1 can be used for the research of cancer.

P38α-IN-11 (Compound 16c) is a p38α inhibitor with a KD value of 586 nM. P38α-IN-11 can be used for research on cervical cancer.

p38 MAP Kinase-IN-2 (Compound 5) is a p38 MAP Kinase inhibitor. p38 MAP Kinase-IN-2 can be used for the research of cancer.

P300-IN-6 is an orally active histone acetyltransferase p300 HAT domain inhibitor with human IC50 values of 7 nM. P300-IN-6 suppresses c-Myc expression, decreases H3K18ac and H3K27ac levels, and inhibits cancer cell proliferation.P300-IN-6 suppresses tumor growth in xenograft mouse models.P300-IN-6 can be used for the research of multiple myeloma.

P2L-003 is a selective PAR2 antagonist with an IC50 of 0.62 μM in HT-29 cells. P2L-003 blocks PAR2-mediated Ca2+ mobilization without affecting PAR1, PAR4, or ATP-mediated signaling and dose-dependently suppresses the downstream MAPK signaling cascades, including ERK1/2 and p38 phosphorylation. P2L-003 can be used for colon cancer research.

OPN-9643 is a covalent inhibitor targeting the central palmitate binding pocket of TEADs with an IC50 of 15 nM, preventing autopalmitoylation and reducing TEAD-driven luciferase activity and canonical TEAD targets, CTGF and CYR61. OPN-9643 can be used for the research of cancer, such as melanoma.

ONO-2921 is an orally active and selective N-type calcium channel blocker. ONO-2921 functionally blocks N-type calcium channels. ONO-2921 reduces paw withdrawal responses during persistent nociception and hyperalgesia to heat in neuropathic pain models. ONO-2921 can be used for research on neuropathic pain and nociceptive pain.

OK-1035 is a selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 100 μM.

OH14 is a cellular FLICE-like inhibitory protein (cFLIP) inhibitor and TNF-related apoptosis-inducing ligand (TRAIL) sensitizer. OH14 selectively binds to the DED1 pocket of cFLIP, disrupting its recruitment to the TRAIL-death inducing signalling complex without affecting procaspase-8 recruitment to FADD, allowing procaspase-8 activation. OH14 promotes TRAIL-mediated apoptosis and impairs cell viability in breast cancer systems when combined with TRAIL. OH14 can be used for the research of breast cancer.

Octoclothepine (Clorotepine), an analog of Clozapine, is a neuroleptic and antipsychotic agent. Octoclothepine exists in enantiomeric forms, where the (+)-form acts as an atypical antipsychotic, while the (-)-functions as a typical antipsychotic. (+)-Octoclothepine exhibits extremely high binding affinity for 5-HT₆ and 5-HT₇ receptors, with Ki values of 0.41 and 0.38 nM; the Ki values of (-)-Octoclothepine are 17.7 and 1.3 nM, respectively. Octoclothepine can be used in research related to schizophrenia.

O-1812 is a selective CB1 ligand. O-1812 is also a very weak AMT inhibitor. O-1812 can be used in the research of chronic pain, migraines, and inflammation.

NSD-IN-5 (Example 47) is a nuclear receptor-binding SET domain (NSD) inhibitor with IC5050 values ​​of 6 and < 1 nM for NSD1 and NSD2, respectively. NSD-IN-5 also exhibits inhibitory activity against Avg KMS11 cells with an IC5050 of 6 nM. NSD-IN-5 may be used in research on multiple myeloma.

NSC 1008 is a selective Ras converting enzyme 1 (Rce1) inhibitor that reduces Rce1 in vitro activity with a human IC50 of 8.9 μM. NSC 1008 demonstrates selectivity for Rce1 by not inhibiting human Ste24 or huamn FTase. NSC 1008 exhibits low cell toxicity, and induces mislocalization of EGFP-Ras from the plasma membrane in cancer cells. NSC 1008 can be used for the research of cancer.

NS-181 is a MetAP2 inhibitor and antiamebic agent with oral effectiveness.NS-181 functionally inhibits methionine aminopeptidase 2, a protein critical for Entamoeba histolytica proliferation. NS-181 exerts antiamebic activity against Entamoeba histolytica, leading to resolution of amebic liver abscess. NS-181 can be used for the research of amebiasis.

NPD15261 (MI102) is a highly selective MYCN inhibitor. NPD15261 reduces the mRNA and protein levels of MYCN in liver cancer cells, inhibits cell proliferation and colony formation, and induces Apoptosis simultaneously. NPD15261 can be used in liver cancer research.

NLRP3-IN-89 is a NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. NLRP3-IN-89 inhibits the NLRP3 inflammasome pathway, reduces IL-1β secretion, and exhibits minimal interference with the NF-κB pathway. NLRP3-IN-89 can be used for the research of Parkinson's disease, frontotemporal dementia, multiple system atrophy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, or brain injury.

NLRP3-IN-86 (Compound 8a), a derivative of Songorine, is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-86 can reduce LPS- and Nigericin-stimulated lactate dehydrogenase (LDH) release (IC50 = 2.69 μM in THP-1 cells and 1.75 μ M in J774A.1 cells). NLRP3-IN-86 can inhibit gasdermin D (GSDMD) cleavage and IL-1β secretion. NLRP3-IN-86 can inhibit cell pyroptosis. NLRP3-IN-86 can be used for research of inflammation.

Nitramisole is a nitrobenzene-heterocycle conjugate and microfilaricide. Nitramisole kills microfilariae of Brugia malayi, Dipetalonema viteae and Litomosoides carinii. Nitramisole can be used for the research of filariasis (Brugia malayi, Dipetalonema viteae, Litomosoides carinii infections).

NFE2L1 activator-1 (Compound 5b) is a potent nuclear factor erythroid 2-related factor 1 (NFE2L1) activator (EC50 = 2.4 µM). NFE2L1 activator-1 effectively resists ferroptosis (Ferroptosis). NFE2L1 activator-1 can specifically activate the NFE2L1 signaling pathway to upregulate GPX4, PSMB7, PSMC4. NFE2L1 activator-1 can be used in cancer research.